Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
“Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all Americans to take charge of their brain health,” said
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, and behavioral and psychological symptoms including agitation. AD is the most common form of dementia and afflicts an estimated 7.2 million individuals in
During Alzheimer’s & Brain Awareness Month, Axsome is working with advocacy and patient communities to raise awareness and share resources, in addition to participating at scientific and medical conferences throughout the year.
To learn more about Alzheimer’s disease advocacy organizations and some of the resources they provide supporting individuals with Alzheimer’s and their family members or caregivers, please visit the following websites:
- Alzheimer’s Association (https://www.alz.org/). The Alzheimer’s Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.
- Alzheimer’s
Foundation of America (https://alzfdn.org/). The Alzheimer’sFoundation of America (AFA) provides support, services and education to individuals, families and caregivers affected by Alzheimer’s disease and related dementias nationwide, and funds research for better treatment and a cure. - Caregiver Action Network (https://www.caregiveraction.org/). Caregiver Action Network (CAN) is the nation’s leading family caregiver organization working to improve the quality of life for the more than 90 million Americans who care for loved ones with chronic conditions, disabilities, or disease, as well as those supporting the living needs of older adults.
- CaringKind (https://www.caringkindnyc.org/). CaringKind is New York City’s leading expert on Alzheimer’s and dementia caregiving. With over 40 years of experience, CaringKind works directly with its community partners to develop the information, tools and training to support individuals and families affected by dementia.
Family Caregiver Alliance (https://www.caregiver.org/). For more than 40 years,Family Caregiver Alliance (FCA) has provided services to family caregivers of adults with physical and cognitive impairments, such as Parkinson’s, stroke, Alzheimer’s and other types of dementia.National Alliance for Caregiving (https://www.caregiving.org/). TheNational Alliance for Caregiving is a non-profit coalition of national organizations who share a vision of a society that values, supports and empowers family caregivers to thrive at home, work and life. Its mission is to build partnerships in research, advocacy, and innovation to make life better for family caregivers.
About
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain
Investors:
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media:
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
References:
- Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2025;21(5).
- Mokdad AH, Ballestros K, Echko M, Glenn S, Olsen HE, Mullany E. The State of
US Health , 1990-2016: Burden of Diseases, Injuries, and Risk Factors Among US States. JAMA 2018;319(14):1444-1472.
Source: Axsome Therapeutics, Inc.
